NCT01843374

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2013-05-17Est. Completion: 2016-01-24

Enrollment target: 571 participants

Locations

Research Site, Scottsdale, Arizona, United States
Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, San Francisco, California, United States
Research Site, Santa Monica, California, United States
Research Site, New Haven, Connecticut, United States
Research Site, Newark, Delaware, United States
Research Site, Tampa, Florida, United States
Research Site, Augusta, Georgia, United States
Research Site, Chicago, Illinois, United States
Research Site, Peoria, Illinois, United States
Research Site, Baltimore, Maryland, United States
Research Site, Baltimore, Maryland, United States
Research Site, Minneapolis, Minnesota, United States
Research Site, New York, New York, United States
Research Site, Rochester, New York, United States
Research Site, Durham, North Carolina, United States
Research Site, Canton, Ohio, United States

Other microbiome trials you might be interested in

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPhase 1Recruiting

Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-CellMesothelioma, MalignantProstatic Neoplasms, Castration-ResistantEndometrial CancerOvarian Clear Cell CarcinomaMetastatic Castration-resistant Prostate Cancer

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, ph…

Tampa, United StatesEst. completion Feb 27, 2030

View Trial →

Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruiting

Thymoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.